NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Not exactly my point. I think the FDA is more concerned with correct therapy for correct subclass(es). It's not about preventing monopolies for them, it's about preventing wrong therapy for the wrong patient. Or a better way of stating it is right therapy for the right patient. In other words, they want a match. If the broad spectrum therapeutic is more efficacious than the narrow spectrum therapeutic, then they don't need a bunch of little niche therapies. As you can imagine, it may be in some cases, broad spectrum is better for first line, and in other cases, narrow spectrum is appropriate for first line.

It would have been very interesting to see what would have happened if Rindopepimut had been initiated on EGFRIII mutation positive patients, but their dose was thereafter quickly overlapped with DCVax-L. The thing is, Rindopepimut was good at eliminating EGFRIII tumor cells from arising after therapy, but of course other mutations continued to multiply. DCVax-L on the other hand, as what one in soccer might call a sweeper, could come in after the surgery/radiation/Rindo had lowered the tumor burden, and cleaned up the other mutations remaining before they metastasized too much.